MAPT and early-onset autosomal dominant Alzheimer disease: These data suggest that this assay can successfully determine abundance changes of endogenous tau surrogate peptides 25–44, 181–190, 212–221 and 243–254, but that the reference standard curve does not accurately quantify the true tau concentration in Alzheimer’s Disease CSF.